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O B J E C T I V E S The purpose of this study was to assess the frequency, manifestation, and severity of
acute adverse reactions associated with administration of several gadolinium-based contrast agents to
patients who underwent cardiac magnetic resonance (CMR) imaging in the EuroCMR (European
Cardiovascular Magnetic Resonance) Registry multinational and multicenter setting.
B A C KG ROUND The frequency, manifestations, and severity of acute adverse reactions associated
with gadolinium-based contrast agents in the speciﬁc setting of cardiovascular magnetic resonance have
not been systematically evaluated yet.
METHOD S This is a multicenter and multinational registry with consecutive enrollment of patients
in 45 European centers. During the current observation, 17,767 doses of gadolinium-based contrast
agent were administered to 17,767 patients. The mean dose was 25.6 ml (range 5 to 80 ml), which is
equivalent to 0.128 mmol/kg (range 0.012 to 0.3 mmol/kg).
R E S U L T S Thirty acute adverse reactions due to contrast administration occurred (0.17%). All
reactions were classiﬁed as mild according to the American College of Radiology deﬁnition. The most
frequent complaints following contrast administration were rashes and hives (9 of 30), followed by
nausea (7 of 30), and anxiety (6 of 30). The event rate ranged from 0.06% (linear nonionic agent
gadodiamide) to 0.47% (linear ionic agent gadobenate dimeglumine). Interestingly, we also found
different event rates between the three main indications for CMR imaging, ranging from 0.1% (risk
stratiﬁcation in suspected coronary artery disease) to 0.42% (viability in known coronary artery disease).
CONC L U S I O N S The incidence of acute adverse reactions after administration of gadolinium-based
contrast in the “off-label” setting of CMR in our population was not different from the incidence in the U.S.
Food and Drug Administration–approved general radiology setting. Thus, the off-label use of gadolinium-
based contrast in CMR should be regarded as safe concerning the frequency, manifestation, and severity of acute
events. (J Am Coll Cardiol Img 2011;4:1171–6) © 2011 by the American College of Cardiology Foundation
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1172ardiac magnetic resonance (CMR) is a
rapidly emerging noninvasive imaging
technique providing high-resolution im-
ages of the heart in any desired plane
ithout application of radiation (1). CMR consists
f several protocols that can be performed sepa-
ately, or in various combinations during a single-
atient examination. For several of those CMR
rotocols, such as myocardial perfusion imaging,
R angiography, or noninvasive tissue character-
zation, gadolinium-based contrast agents are
ecessary.
See page 1177
Gadolinium-based contrast agents are considered
generally safe in radiology practice. The incidence
of adverse reactions is relatively low compared with
that of iodinated contrast agents used for computed
tomography (2–7). Nevertheless, the frequency,
manifestation, and severity of acute adverse reac-
tions associated with gadolinium-based contrast
agents in the specific setting of CMR have not been
systematically evaluated yet. Thus, the use
of gadolinium-based contrast agents for
CMR imaging is still considered as an
“off-label” use in the United States and
many European countries.
Consequently, the purpose of this study
was to assess the frequency, manifestation,
and severity of acute adverse reactions asso-
ciated with administration of several gadolinium-
based contrast agents to patients who underwent
CMR imaging in the EuroCMR (European Cardio-
vascular Magnetic Resonance) Registry multinational
and multicenter setting.
M E T H O D S
Study population and data management. The basis
f the current paper is the EuroCMR Registry
ncluding 11,040 consecutive patients of the Ger-
an pilot phase (April 2007 to January 2009) and
delle Ricerche/Regione Toscana “G. Monasterio,” Pisa, Italy; ¶Depar
Germany; #Hahnemann University Hospital, Drexel University College
ment of Internal Medicine, Krankenhaus Benrath, Düsseldorf, Germany
Donauklinikum Tulln, Tulln, Austria; ‡‡Department of Cardiology, Vrije Un
§§Centre Hospitalier Universitaire Vaudois—CHUV University of Laus
Sciences, King’s College, London, United Kingdom; and the ¶¶Depart
Stuttgart, Germany. The EuroCMR Registry is supported by unrestr
Siemens Healthcare. Dr. Schwitter has received research support from B
they have no relationships relevant to the contents of this paper to discloManuscript received April 25, 2011; revised manuscript received June 27, 20,677 patients of the ongoing European registry
March 2009 to March 2011). All data were pro-
pectively collected by trained personnel with the
se of online case record forms provided by the
nstitut für Herzinfarktforschung Ludwigshafen,
niversity of Heidelberg, Germany via a SSL-
ecured Internet connection, and stored on a central
erver (8,9). Each participating center (Online Ap-
endix) appointed a senior cardiologist or radiolo-
ist as a local investigator responsible for the data
uality of each individual patient entered in the
egistry. A plausibility check was directly carried out
fter submitting the data to avoid further queries as
ar as possible. Data collection and management
ere approved by the ethics committee.
Analysis cohort. All 17,767 patients (90% of 19,717)
eceiving contrast media were included in the anal-
sis. All patients received the contrast media in
ompliance with the current American College of
ardiology Foundation/American College of Radi-
logy/Society of Cardiovascular Computed To-
ography/Society of Cardiovascular Magnetic Res-
nance/American Society of Nuclear Cardiology/
orth American Society of Cardiovascular
maging/Society for Cardiac Angiography and In-
erventions/Society of Interventional Radiology ap-
ropriateness criteria for CMR imaging (8–10). The
ompleteness of the analysis dataset was higher than
8%. The patient charts of all acute adverse reactions
ue to contrast media were reviewed centrally and
ategorized by the project management.
Variables and deﬁnitions. All variables assessed were
re-defined and were collected directly from pa-
ients and/or from medical records. Variables in-
lude demographic data, history, and indications for
MR; procedural parameters; as well as complica-
ions (8,9). Complications caused by acute adverse
eactions to contrast media ( onset within 60 min
fter administration) are defined according to the
merican College of Radiology (11) criteria and
an be viewed in Table 1.
Statistics. Statistical analysis was performed by the
Biometrics Department of the Institut für Herzin-
nt of Cardiology, Klinikum Coburg, Coburg,
edicine, Philadelphia, Pennsylvania; **Depart-
epartment of Internal Medicine and Cardiology,
sity Medical Centre, Amsterdam, the Netherlands;
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educational grants from Medtronic, Inc. and
-Schering. All other authors have reported thattme
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1173farktforschung, Ludwigshafen, Germany, which is
chaired by senior statistician Steffen Schneider, PhD.
Absolute numbers and percentages were computed
to describe the distribution of the different contrast
media and the rate of adverse reactions in the
patient population. Medians (with ranges) and
means (with standard deviation) were calculated to
describe the characteristics of contrast media and to
characterize the patients with adverse reactions.
Categorical parameters were compared by using
Fisher exact test and continuous variables by using
Wilcoxon rank sum test. However, the low rates of
adverse events preclude most significance tests and
the absence of pre-specified statistical hypothesis in
the registry allows descriptive comparisons in most
cases only. All analyses were performed using the
SAS statistical package (version 9.2, SAS Institute,
Cary, North Carolina).
R E S U L T S
Acute adverse reactions by severity. During the cur-
ent observation, 17,767 doses of gadolinium-based
ontrast agent were administered to 17,767 patients
ndergoing CMR imaging. The mean dose was
5.6 ml (range 5 to 80 ml), which is equivalent to
.128 mmol/kg (range 0.012 to 0.3 mmol/kg).
uring and immediately after the CMR procedure,
0 acute adverse reactions due to contrast adminis-
ration occurred (0.17%). No relation between acute
eactions and the dose administered was detected
sing Wilcoxon rank sum test (p  0.07). All
eactions were classified as mild (Table 1). There
ere no moderate or severe reactions or death due
o contrast administration. Furthermore, we did not
bserve an accumulation of events in a single center
r a cluster of centers.
Acute adverse reactions by type of contrast media.
The EuroCMR Registry individually recorded the
adverse reactions for the following contrast media:
gadopentetate (e.g., Magnevist), gadoteracid (e.g.,
Dotarem), gadobenat (e.g., Multihance), gad-
obutrol (e.g., Gadovist), gadoteridol (e.g., Pro-
hance), and gadodiamid (e.g., Omniscan). All other
contrast media were summarized as “others.” Eigh-
teen of the 45 centers exclusively used a single
contrast agent for all patients (gadopentetate: n 
5, gadoteracid: n  1, gadobenat: n  0, gad-
butrol: n  6, gadoteridol: n  2, gadodiamid:
 4). All other centers used at least 2 or more
ifferent contrast agents in their clinical routine.
Table 2 displays the adverse reactions categorizedy severity (all mild) and the specific contrastedia. Note that the event rate ranges from 0.06%
o 0.47% between the different agents. However, we
id not find a relation between the individual event
ates and the specific characteristics of the agents,
uch as molecular structure or chelate stability
Table 3).
The characteristics of all patients with acute
dverse reactions sorted by contrast agent type can
Table 1. Classiﬁcation of Severity and Manifestation of Adverse
to Contrast Media
Mild
Signs and symptoms appear self-limited without evidence of pro
urticaria with mild pruritus, transient nausea, 1 episode of em
Nausea, vomiting Pallo
Cough Flus
Warmth Chil
Headache Swe
Dizziness Rash
Shaking Nas
Altered taste Swe
Itching Anx
Treatment: Requires observation to conﬁrm resolution and/or lack
may require treatment in some cases. Patient reassurance is u
Moderate
Signs and symptoms are more pronounced. Moderate degree of
focal or systemic signs or symptoms, including:
Tachycardia/bradycardia Bron
Hypertension Lary
Generalized or diffuse erythema Mild
Dyspnea
Treatment: Clinical ﬁndings in moderate reactions frequently requ
treatment. These situations require close, careful observation f
progression to a life-threatening event.
Severe
Signs and symptoms are often life-threatening and include:
Laryngeal edema (severe or rapidly progressing) Con
Profound hypotension Unr
Clinically manifest arrhythmias Card
Treatment: Requires prompt recognition and aggressive treatmen
treatment frequently require hospitalization.
Table 2. Adverse Reactions Categorized by Severity and Agent
Advers
Agent
Examinations
(n)
Mild
(n)
Moderat
(n)
Gadopentetate (e.g., Magnevist) 7,490 15 0
Gadoteracid (e.g., Dotarem) 1,208 3 0
Gadobenat (e.g., Multihance) 428 2 0
Gadobutrol (e.g., Gadovist) 2,201 5 0
Gadoteridol (e.g., Prohance) 254 1 0
Gadodiamid (e.g., Omniscan) 3,097 2 0
Other 3,089 2 0Reactions
gression (e.g., limited
esis) and include:
r
hing
ls
ats
, hives
al stufﬁness
lling: eyes, face
iety
of progression and
sually helpful.
clinically evident
chospasm, wheezing
ngeal edema
hypotension
ire prompt
or possible
vulsions
esponsiveness
iopulmonary arrest
t; manifestations ande Reactions
e Severe
(n) N (%)
0 15 (0.20)
0 3 (0.25)
0 2 (0.47)
0 5 (0.23)
0 1 (0.39)
0 2 (0.06)
0 2 (0.06)Total 17,767 30 0 0 30 (0.17)
p
r
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1174be viewed in Table 4. The most frequent com-
laints following contrast administration were
ashes and hives (9 of 30), followed by nausea (7 of
Table 3. Adverse Reactions Categorized by Agents= Speciﬁc Cha
Agent Molecular Structure
Gadopentetate (e.g., Magnevist) Linear
Gadoteracid (e.g., Dotarem) Cyclic
Gadobenat (e.g., Multihance) Linear
Gadobutrol (e.g., Gadovist) Cyclic
Gadoteridol (e.g., Prohance) Cyclic
Gadodiamid (e.g., Omniscan) Linear
Other N/A
Log Ktherm  chelate stability; N/A  not applicable.
Table 4. Patient Characteristics, Gadolinium Dose, and Characte
All
Gadopentetate
(Magnevist)
Gadoteracid
(Dotarem)
All 30 15 3
Age, yrs, mean 54.0 52.0 46.7
SD 17.2 19.7 19.3
Median 57.0 58.0 53.0
Range 16–77 16–74 25–62
Sex
Male, % 76.6 73.3 100.0
Female, % 23.3 26.7 0
Contrast dose, ml,
mean
21.8 23.5 23.3
SD 8.7 7.6 11.7
Median 20.5 24.0 28.0
Range 7–40 7–36 10–32
Category of reaction
Mild 30 15 3
Moderate 0 0 0
Severe 0 0 0
Symptoms
Nausea 7 2 0
Vomiting 5 2 0
Warmth 3 2 0
Headache 2 1 0
Dizziness 5 3 0
Altered taste 1 0 0
Itching 7 2 1
Flushing 6 1 1
Chills 2 1 0
Sweats 2 1 0
Rash/hives 9 3 2
Swelling of eyes/face 1 1 0
Anxiety 6 6 0
Treatment
Observation 18 10 3
Antihistamines 10 3 1Steroids 11 3 130) and anxiety (6 of 30). Of 30 patients with
adverse events, 18 required short-term observation
and 11 of them were treated with steroids and/or
teristics
Ionic/Nonionic Log Ktherm Reactions (%)
Ionic 22.1 0.20
Ionic 25.8 0.25
Ionic 22.6 0.47
Nonionic 21.8 0.23
Nonionic 23.8 0.39
Nonionic 16.9 0.06
N/A N/A N/A
ics of Reaction
adobenat
ultihance)
Gadobutrol
(Gadovist)
Gadoteridol
(Prohance)
Gadodiamid
(Omniscan) Other
2 5 1 2 2
63.0 58.0 48.0 62.0 56.0
3.5 15.4 — 5.7 18.4
63.0 49.0 48.0 62.0 56.0
17–72 41–77 48–48 58–66 43–69
100.0 40.0 100.0 100.0 100.0
0 60 0 0 0
17.5 13.2 40.0 16.0 29.5
3.5 11.7 — 5.7 3.5
17.5 12.5 40.0 16.0 29.5
15–20 10–21 40–40 12–16 27–32
2 5 1 2 2
0 0 0 0 0
0 0 0 0 0
1 1 0 2 1
0 0 0 2 1
1 0 0 0 0
0 0 0 0 1
0 0 0 2 0
0 0 0 0 1
1 2 1 0 0
1 3 0 0 0
0 1 0 0 0
0 1 0 0 0
1 2 1 0 0
0 0 0 0 0
0 0 0 0 0
2 3 1 2 2
1 2 0 2 1racrist
G
(M1 2 1 2 1
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1175antihistamines as a precaution. All patients im-
proved during observation and could be discharged
later. No one needed to stay as an inpatient due to
the adverse contrast reaction.
Acute adverse events by CMR indication. When fo-
cusing on the reactions sorted by the initial CMR
indication, we found different event rates between
the three main indications (8), ranging from 0.1%
in the group of basically healthy patients undergo-
ing CMR for risk stratification in suspected coro-
nary artery disease to 0.42% in patients undergoing
CMR for detection of myocardial viability in the
setting of left ventricular dysfunction and known
coronary artery disease (p  0.006) (Table 5).
D I S C U S S I O N
Only 30 of our 17,767 CMR patients suffered from
gadolinium-related acute adverse reactions. All re-
actions were classified as mild and only 18 of those
30 patients needed short-term observation before
discharge. This is unique in that the present dataset
is the first to systematically evaluate the frequency,
manifestation, and severity of acute adverse reac-
tions associated with gadolinium-based contrast
agents in the specific setting of CMR in a multi-
national and multicenter setting.
CMR in comparison to general radiology use. The
overall rate of acute adverse reactions in our 17,767
patients undergoing CMR was 0.17%. This is
completely in line with the observations in the
setting of the U.S. Food and Drug Administration
(FDA)-approved general radiology use of gadolin-
ium contrast, reporting adverse reaction rates be-
tween 0.04% and 2.2% (3–7,12–14).
Interestingly, in our cohort, only mild reactions
occurred (see definition in Table 1), whereas in the
general radiology use, up to 17.2% of reactions were
graded as moderate (12) and up to 6.3% of reactions
were graded as severe (12).
Differences between groups. Focusing on the indi-
vidual reaction rates for the different contrast media
recorded by the registry, we found a range of 0.06%
and 0.47% between the different agents. This find-
ing is in line with the findings of a recent retro-
spective analysis of the FDA Adverse Event Re-
porting System (14). As suggested by Prince et al.
(14), a possible explanation for this finding could be
differences between the molecular structure and
chelate stability in the different agents. However, as
displayed in Table 3, this does not seem to play a
relevant role for acute adverse reactions in our
population. Nevertheless, molecular structure andchelate stability may play a role in long-term com-
plications such as nephrogenic systemic fibrosis.
Unfortunately, long-term follow-up is not available
for this current dataset (see the Study limitations
section).
In addition, we found different reaction rates
depending on the indication for CMR scanning
(Table 5). We believe that this finding is most likely
explained by the different burden of disease in the
different patient groups. Whereas basically healthy
people undergoing CMR for risk stratification for
suspected coronary artery disease have the lowest
rate of gadolinium-related adverse events, in com-
parison the sick group of patients presenting with
left ventricular dysfunction due to known coronary
artery disease has the highest rate of events. This
finding may even suggest that in this group some of
the often unspecific symptoms such as nausea or
anxiety (Tables 1 and 4) that had been interpreted
as gadolinium-related symptoms may also be due to
the underlying disease (e.g., heart failure). In fact,
based on this observation, one may speculate that
the reaction rate truly caused by the gadolinium
administration could be even lower than currently
reported.
Study limitations. The data presented was collected
as part of a registry. Thus, it is important to keep in
mind that a prospective randomized trial may be the
best tool to prove a certain principle, but only a
registry can reveal if the results of controlled trials
hold true in the multinational multicenter clinical
routine (8). Nevertheless, based on the registry
structure, we can only report acute reactions; sys-
tematic long-term follow-up (e.g., with regard to
nephrogenic systemic fibrosis) is not available.
However, we do not expect cases of nephrogenic
systemic fibrosis in our population, because patients
included in the registry were scanned in compliance
with our registry protocol (8,9) and the actual
American College of Cardiology Foundation/
American College of Radiology/Society of Cardio-
vascular Computed Tomography/Society of Car-
diovascular Magnetic Resonance/American Society
of Nuclear Cardiology/North American Society of
Table 5. Adverse Reactions Categorized by Indication
All RS CAD MYO/CM
Mild adverse
reactions
30/17,767 (0.17) 7/7,285 (0.10) 10/5,813 (0
Values are n/N (%). See references 8 and 9 for details.
RS CAD  risk stratiﬁcation in suspected coronary artery disease; MYO/CMP
myocarditis or cardiomyopathy; Viability  work-up of myocardial viability i
disease.P Viability
.17) 9/2,146 (0.42)
 work-up of suspected
n known coronary arteryCardiovascular Imaging/Society for Cardiac An-
r
c
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1176giography and Interventions/Society of Interven-
tional Radiology appropriateness criteria for CMR
imaging (10), ensuring sufficient renal function by
blood testing (or reviewing of recent lab results)
before the administration of gadolinium.
Clinical implications. The current dataset demon-
strates the safety of gadolinium in a multinational
and multicenter setting of CMR. The rate of acute
contrast-related adverse reactions is low and similar
to that reported in the literature in a general
radiology setting (3–7,12–14). Thus, we believe
that despite the fact that there currently is no FDA
approval of gadolinium for CMR in the United
States and many European countries, the off-label
use does not bring any additional risks for the
patient. In fact, datasets such as this, when com-
bined with efficacy studies, may facilitate FDAproved MRI contrast agent: review of
23,553 administrations of gadobenate
1
tional Radiology. J
2006;48:1475–97.C O N C L U S I O N S
The incidence of acute adverse reactions after ad-
ministration of gadolinium-based contrast in the
off-label setting of CMR in our population was not
different from the incidence in the FDA-approved
general radiology setting. Thus, the off-label use of
gadolinium-based contrast in CMR should be re-
garded as safe concerning the frequency, manifes-
tation, and severity of acute events.
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